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Cerebral protection during carotid stenting using
flow reversal
Juan C. Parodi, MD,a Luis M. Ferreira, MD,a Gregorio Sicard, MD,b Ricardo La Mura, MD,a and
Samuel Fernandez, MD,a Buenos Aires, Argentina; and St Louis, Mo
Background: Carotid angioplasty and stenting can be used in stroke prevention in high-risk patients. As embolic
complications can occur during carotid angioplasty and stenting, a device was developed to protect from cerebral
embolization.
Methods: Between September 1999 and May 2002, carotid angioplasty and stenting was performed in 100 patients (84
men; mean age, 69.2 years) with symptomatic (26%) or asymptomatic (74%) severe carotid artery stenosis. Wallstents
were used in all cases with selective pre-dilatation. Cerebral protection devices (Parodi Anti-Emboli System [PAES],
ArteriA, San Francisco, Calif) were used in all patients. All patients were evaluated by a neurologist, both before and after
the procedure. According to the criteria set forth by the large trials, the occurrence of minor, major or fatal stroke and
myocardial infarction (end points) within 30 days and follow-up were determined as end points. Data were collected
prospectively.
Results: The overall perioperative stroke and death rate was 3% (1 noncorresponding minor stroke, 1 hemorrhagic stroke,
and 1 cardiac event). Four patients developed postoperative transient neurologic events (three related to hemodynamic
instability and the fourth due to postoperative embolization). The overall technical success rate for carotid angioplasty
(protection device placed in position percutaneously) was 99%.
Conclusion: The efficacy and safety of carotid angioplasty and stenting with PAES are confirmed. This innovative
protection device may prevent the debris released by angioplasty from entering the cerebral circulation. Further
investigation is warranted. (J Vasc Surg 2005;41:416-22.)Carotid artery stenting (CAS) is emerging as an alter-
native to carotid endarterectomy.1-4 Although evidence is
scarce, CAS is being proposed increasingly to treat high-
risk surgical candidates for carotid endarterectomy.5-8
From the information revealed by transcranial Dopp-
ler monitoring,9-10 in vitro studies using carotid endar-
terectomy surgical specimens,11-12 and the results of the
trials that used protection devices, it became obvious
that the main limitation of CAS is the potential occur-
rence of cerebral embolization during the procedure.
Several protection devices have been explored in the
past, and most of the reports indicate the beneficial effect
of cerebral protection during CAS.13 Having used most
of the systems, and learning about their limitations, we
initiated an assessment of safety and efficacy of a novel
cerebral protection device used during carotid stenting.
The new method is based upon an observation made
during carotid endarterectomy. After clamping the arteries
and inserting a shunt in the internal carotid artery, leaving
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416the other end of the shunt open, flow in the middle cerebral
artery was reversed consistently. Assessment of the charac-
teristics of the flow was performed with transcranial Dopp-
ler monitoring (TCD) (Fig 1).
A percutaneous method was developed that reproduces
the circumstances observed during flow reversal. We report
here our clinical experience with this method. Before embark-
ing in the clinical application of the method, two different
animal studies were completed that showed the safety and
efficacy of the method in the experimental model.14-15
METHODS
This study was approved by the hospital internal review
board and all patients gave informed consent.
Between September 1999 and May 2002, CAS was
performed under local anesthesia in 100 consecutive pa-
tients (84 men, mean age, 69.2 years). All patients had
carotid artery stenosis 70% (symptomatic, 26%; asymp-
tomatic, 74%.). The diagnosis of high-grade artery stenosis
was made with duplex ultrasound scanning. In detail, as
direct criteria for the local degree of stenosis, systolic peak
flow velocity within the stenosis, and the post-stenotic
internal carotid artery, diastolic peak flow velocity in the
stenosis, and the internal carotid artery-common carotid
artery index were determined. The residual vessel lumen in
the B-mode image and the color-code residual vessel area
were also documented. As a key feature, stenosis70% was
diagnosed if the peak systolic velocity was 230 cm/s or
peak diastolic velocity was100cm/s, index was4.0, and
arter
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graphically before the stent procedure.
All patients were high-risk candidates for carotid end-
arterectomy according to the following criteria: history of
congestive heart failure, coronary artery disease needing
coronary artery bypass grafting or percutaneous translumi-
nal angioplasty; severe chronic obstructive pulmonary dis-
ease (forced expiratory volume in 1 second 0.8 L); renal
insufficiency (serum creatinine3 mg/dL); first or second
restenosis after endarterectomy; hostile neck (giant heman-
gioma, radical neck dissection, radiotherapy). All patients
had one or more of these risk factors (Table I).
Two patients underwent combined CAS and coronary
artery bypass grafting procedures.
Premedication consisted of a daily dose of aspirin (325
mg) and clopidogrel (75 mg) initiated 3 days prior to the
procedure. The patients with the combined procedures did
not receive clopidogrel.
Preoperative diagnosis of stenosis was made by color
duplex scanning. Symptomatic patients received a com-
puted tomographic scan of the brain.
The procedure was performed under local anesthesia in
the operating room. OEC 9800 C-Arm (GE Healthcare)
equipment was used in every case.
The common femoral artery and vein were cannulated
percutaneously using the Seldinger technique. A 10F
sheath was introduced in the artery and a 6F sheath was
introduced in the vein. An arch arteriogram was performed
with a pigtail catheter in the left anterior oblique position.
In patients with a serum creatinine level 2 mg/dL, the
arch study with iodinated contrast media was not done, and
the information of the anatomy of the arch was obtained
from magnetic resonance angiography performed before
the procedure. Gadolinium was used instead of iodinated
contrast to visualize the branches once they were cannu-
Fig 1. Reverse middle carotid artery flow, performed
clamped and a shunt was inserted in the internal carotidlated in those patients.The common carotid arteries were cannulated accord-
ing to standard techniques. The initial floppy wire was
exchanged by an Amplatz super-stiff wire (Boston Scientific
Corp.) once the catheter was inserted in the external ca-
rotid artery.
The Parodi Antiembolysm System (PAES) (ArteriA
Medical Science, San Francisco, Calif) was placed in posi-
tion by using the stiff wire as a guide. The PAES is a closed
system that allows internal carotid artery flow arrest, con-
tinuous passive internal carotid artery flow reversal, or
augmented active internal carotid artery flow reversal, such
transcranial Doppler scanning, after the arteries were
y.













Tobacco use, current or within previous year 49
Diabetes mellitus 18
Symptomatic coronary artery disease 27
Previous coronary bypass 14
Previous PTCA 11
Coronary ischemia in cardiac tests 32
Congestive heart failure 8
Q-wave MI 10
Contralateral ICA stenosis 70% 9
Contralateral ICA occlusion 5
TIA, Transient ischemic attack; PTCA, percutaneous transluminal angio-
plasty; MI, myocardial infarction; ICA, internal carotid artery.usingthat any particles that are released during CAS, will pass
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arteriovenous conduit filter outside the body. We demon-
strated backflow in every patient by opening the three-way
stopcock situated distal to the external filter and immedi-
ately proximal to the venous sheath. In any event, we
applied additional suction with a syringe during the critical
steps of the procedures (crossing the lesion, balloon defla-
tion, and stent deployment). An addition, aspiration was
applied before a contrast injection and immediately after
obtaining the images. The flow reversal was also docu-
mented directly by a dynamic angiography and Doppler
monitoring (intracranial internal carotid artery or MCA).
TCD monitoring was used according to device availability
and missing temporal bone window for insonation.
The three components of the device were specifically
designed to allow retrograde flow in the internal carotid
artery and minimize margination of particles or collection
of material that could subsequently embolize (Fig 2):
1. PAEC. This is a 9.5F, 90-cm-long, guide-catheter with a
funnel shape balloon on the tip (Fig 3). This atraumatic
balloon allows the occlusion of the common carotid artery
and flow reversal. It also serves as the access port for the
stent delivery system and other therapeutic devices.
2. PEB (Parodi External Balloon). A soft atraumatic oval
balloon mounted on a 0.019-inch hypo tube, a low-
profile hollow guidewire, that allows the inflation of the
balloon. The distal, shapeable, floppy guide wire facili-
tates easy navigation into the external carotid artery.
3. BRS (Blood Return System). This component is a con-
duit that connects the side flow reversal port of the
PAEC to a venous sheath. The BRS contains a 180-
micron filter that collects particulate debris before the
Fig 2. The three components of the device designed to
sequence of the Parodi device. Placement of Parodi’s
Inflation of the CCA balloon with forward ICA flow ma
balloon with inversion of ICA flow through Parodi’s g
blood-filtered line to a femoral vein introducer (c).blood re-enters the venous system.Flow reversal technique. The first step is the place-
ment of the PAEC. This can be done using any of the
accepted techniques for guide catheter placement in the
carotid artery. The PEB is then placed through the dedi-
cated proximal port of the PAEC and navigated under
fluoroscopic guidance into the external carotid artery. The
third step is purging and attaching the BRS to a 6F venous
sheath. The venous sheath can be placed in the ipsilateral or
contralateral femoral vein (Fig 4). Once the device is in
position, the CCA is occluded with the PAEC and the PEB
is inflated in the external carotid artery. Opening the BRS
stopcock initiates continuous flow reversal through the
retrograde flow in the internal carotid artery. Schematic
g catheter in the CCA below the stenotic lesion (a).
ed based on retrograde ECA flow (b). Inflation of ECA
g catheter, which is then externally connected with a
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with selective pre-dilatation. The wallstent was dilated with a
5- or 5.5-mm diameter balloon. One milligram of atropine
was injected intravenously prior to balloon dilatation.
The procedure was done under local anesthesia. Intol-
erance was manifested as a loss of consciousness.
A final arteriogram with intracranial views was per-
formed in every patient. Independent neurologists assessed
the neurologic status of the patients before and after the
procedure. The neurologists also conducted a predischarge
visit.
Statistics continues variables are presented as median
(range).
RESULTS
The overall perioperative (30 days or in-hospital) stroke
and death rate was 3% (1 contralateral minor stroke after
cardiac surgery performed concomitantly, 1 hyperperfusion
syndrome, and 1 fatal myocardial infarction).
Transient neurologic systems developed in four pa-
tients in the perioperative period (three related to hypoten-
sion and the fourth due to postoperative embolization 24
hours after treatment). Each patient had TCD monitoring
and a computed tomography scan to rule out emboli or
infarcts. The first three patients were restored to normal
Fig 4. The blood return system attaches to a 6F venous sheath
and contains a filter that purges particulate debris before the blood
re-enters the venous system. Opening the blood reverse system
stopcock initiates continuous flow reversal through the arterio-
venous shunt.clinical status as soon as the blood pressure was normalized.The latter patient, who had two hemispheric transient
ischemic attacks in the recovery room, was successfully treated
with dextran. TCD monitoring disclosed microemboli and
50 high intensity transitory signals (HITS) per hour, which
cleared after 30 minutes of treatment (Table II).
The overall technical success rate for CASwas 99%. The
only patient who could not be treated percutaneously was
successfully treated endoluminally by approaching the
proximal common carotid artery with a 3-cm incision
placed at the base of the neck. Flow reversal was created
after clamping the common carotid artery and connecting
the side port of the arterial introducer to the side port of a
venous introducer inserted in the internal jugular vein.
Particles of different sizes were recovered in the inter-
posed filter in all patients. TCD monitoring was used in 76
patients. No embolic signals were registered during reversal
of flow. In some patients, TCD showed intracranial internal
carotid artery or middle carotid artery flow reversal, and in
others there was sufficient collateralization coming from
the anterior cerebral artery. The average flow reversal time
was 200 seconds (200.70 34.39, range, 113 to 287) in a
small group of patients in whom the times of different
stages were recorded. Because of lengthening occlusion
time, some procedures were completed in stages without
sequelae.
Seventy-seven patients were discharged the following
day. Except for three patients, the rest were discharged the
second day. Patients who experienced complications had a
prolonged extended hospital stay.
Complications. Three patients suffered a temporary
asystole early in our experience, without consequences.
Bradycardia was recorded in 16% of the patients and hypo-
tension in 11%. Once the policy of discontinuing all anti-
hypertensive drugs the day before was adopted, hypoten-
sion was rarely seen.
Inconsequential groin hematoma developed in six pa-
tients, but none needed a blood transfusion or drainage
(Table III).
A minor contralateral stroke occurred in one patient
after a combined procedure, which resolved partially after
30 days.
One patient who had been discharged the day after of
Table II. Periprocedural end points within 30 days
Minor stroke (non-corresponding) 1
Major stroke (intracranial hemorrhage) 1
Fatal stroke (intracranial hemorrhage) 1
Fatal myocardial infarction 1
Perioperative stroke and death rate 3
Table III. Intraoperative complications in 100 patients
Temporary asystole 3
Bradycardia 16
Intra operative PTCA 1
PTCA; Percutaneous transluminal angioplasty.the procedure came back in 3 days complaining of severe
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admitted to the hospital for blood pressure control. Despite
treatment, a massive hemispheric hematoma developed and
the patient died.
The third patient suffered prolonged hypotension and
bradycardia that started during the procedure and suffered
an acute myocardial infarction, despite an attempt to treat
the cardiac ischemia with coronary stent-assisted balloon
angioplasty. This patient had a past history of syncope and
a diagnosis of hypersensitivity of the carotid sinus.
DISCUSSION
Many investigators consider cerebral embolization the
Achilles heel of CAS. Information provided by the use of
TCD during CAS, as well as particles retrieved by the
multiple protection devices used in clinical trials, indicate
that embolization is universal during CAS.5-8 This finding
was also corroborated in two in vitro studies that used
endarterectomy specimens.11-12
Consequences of cerebral embolization during CAS
are not yet completely understood, but common sense
dictates that findings would depend upon the sensitivity of
the method of assessment. In a recently published study,
diffusion-weighted magnetic resonance imaging (DW-
MRI) after CAS in which filters were used for protection
showed 22.7% of cerebral diffusion defects.16In this paper,
new ischemic lesions were seen in postprocedure DWMRI
in 10 patients, but only one had sustained a major stroke.
No adverse neurologic deficits were associated with the
other nine.
Cognitive studies, although still inconclusive, suggest
that particles embolizing the brain are not inconsequential.
The group from Leicester reported significant cognitive
changes in patients who embolized (detected by TCD)
10 particles during carotid dissection as part of a carotid
endarterectomy.17 However, these were not associated
with an adverse clinical outcome. So, “non-clinical” conse-
quences of embolization depends on the method used to
detect them.
In our initial study published in the Journal of Vascular
Surgery in 2000,18 we indicated the trend towards an
increase in the incidence of complications in unprotected
patients (9.53% of neurologic events in the unprotected
group vs 0 in the protected group). In the same study, in
which TCD was routinely used, we found that the only
system that produced noHITS during the protected period
was the PAES.
It is now becoming more evident that all protection
devices provide some degree of protection against cerebral
embolization. In a registry of CAS, Wholey et al13 reported
5.29% rate of stroke/mortality in the unprotected group,
whereas the protected group had an incidence of 2.23 %.
There are stages during CAS in which the brain is not
protected: Performing the arch arteriogram, cannulating
the arteries, and advancing the sheath inside the common
carotid artery. This consideration applies to all the protec-
tion devices, including the PAES.In addition, devices like the PercuSurge (PercuSurge
Inc, Sunnyvale, Calif) or filters that cross the stenotic lesion
have the risk of disrupting and embolizing material, as we,
and others, have documented. Ohki et al11 reported that
12% of the particles generated during an in vitro procedure
were produced during this stage. Coggia et al12 reported,
also in an in vitro study, that crossing the lesion produced
more than 50,000 particles. In two studies of endarterec-
tomy specimens, thrombus lining the carotid plaque was
found in 24% and 48% of the cases.19-20
Using the PercuSurge system, we learned that HITS
occurred throughout the procedure. The same finding was
published by Al-Mubarak et al21 from the Lennox Hill
Heart and Vascular Institute in New York. Obviously,
particles were traveling to the middle cerebral artery
through the external carotid artery flow.
We found that crossing the lesion while using filters
produced showers of particles. HITS also appeared in the
TCD monitor throughout the procedure, caused by parti-
cles crossing the filter or getting around the filter. The
typical porous size of filters is 120 microns. Animal studies
have reported that particles larger than 50 microns pro-
duced lesions.22
A recently published article indicated that filters used in
in vitro studies miss 2.3% to 18% of the particles injected
proximally to the filters23; the level of tortuosity of the
vessels causes differences.
Klaus Mathias,24 the physician who first performed a
carotid angioplasty, reported in the European Society for
Vascular Surgery on September 29, 2001 that application
of filters had inconveniences in a high proportion of pa-
tients: 27% needed pre-dilatation, 18% needed a reposition-
ing of the filter, and problems with retrieval occurred in 7%.
On occasions a “buddy wire” was used to allow the
advancement of the filter along a tortuous artery. Filters
may become full of material and the excess material will
migrate as soon as the filter is retrieved.
Strokes are still significant in the trials in which filters
are used. The Stenting and Angioplasty with Protection in
Patients at High Risk for Endarterectomy (SAPPHIRE)
trial reported a 3.8% stroke rate within 30 days,5 and the
ACCULINK for Revascularization of Carotids in High-
Risk Patients (ARCHeR) trial reported 5.3%.6
Balloons and filters placed in the distal internal carotid
artery can induce spasm and damage to the intima. Dissec-
tions of the internal carotid artery were reported with the
use of PercuSurge.
The PAEC is a guiding sheath with an occlusion bal-
loon attached at the distal end of the catheter. The main
lumen has an inner diameter of 7F that allows the passage of
balloons and stents. Once the PAEC is inserted in the
common carotid artery, the occlusion balloon attached on
the outer surface of the PAEC, as well as the ECA occlusion
balloon, is inflated, thereby occluding inflow to the carotid
bifurcation while maintaining access to the carotid bifurca-
tion lesion through the main lumen. The side port of the
PAEC is then connected to a sheath that is percutaneously
inserted into the femoral vein to create a temporary arte-
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external carotid occlusion balloon, will create reversal of
flow in the internal carotid artery. Thus, particles of all sizes
will flow retrograde through the PAEC and can be cap-
tured.
Once reversal of flow is established, CAS can be safely
performed with a guide wire of choice. Of note is that the
lesion is not manipulated with any device until cerebral
protection is achieved, and that particles of all sizes are
recovered with the reversed flow. This technique allows
cerebral protection before lesion crossing, avoiding the
chances of generating embolic particles and potential neu-
rologic complications.
The PAES device overcomes most of the problems
encountered with balloons and filters, such as failure to
cross the lesion, embolization during lesion crossing, fail-
ure to capture all emboli, or detachment of filter or balloon
components. It has its own inconveniences, however. Its
large profile requires the use of large introducers (10F), and
the 9F sheath (PAEC) is somewhat bulky when tortuous
arteries are negotiated. Intolerance to balloon inflation is
much less than what was predicted. All procedures were
completed despite a 3% rate of clinical intolerance in the
present series.
Criado et al25 reported a very intriguing study, suggest-
ing that reversal of flow was better tolerated than balloon
occlusion of the internal carotid artery.25 Their hypothesis
was that flow reversal enhances collateral flow to the circle
of Willis.
In any event, reversal of flow in the internal carotid
artery assures the surgeon that no particles will migrate to
the brain and lesion crossing becomes safe, as well as
removal of thrombus from the lesion. A recent case of a
symptomatic floating thrombus in the ICA that we success-
fully treated using the PAES will be reported separately.
Our results using the PAES compare favorably with
trials or registers of CAS performed in a high-risk group of
patients. It should be noted, however, that we did not use
troponin to rule out acute myocardial infarction, but the
stroke and mortality rate of the present series is somewhat
lower than other presented series. Other authors reported
results using the PAES that were very similar to ours.26-27For
the few cases in whichwe expect intolerance, the combination
of reversal of flow and filters could be an effective alternative.28
CONCLUSION
This prospective study demonstrated the safety of CAS
with PAES in high-risk patients. This innovative protection
device may prevent debris released by carotid angioplasty
from entering the cerebral circulation. Further confirma-
tory studies are warranted.
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